Quotes 5-day view Delayed Swiss Exchange
06/27/2022
06/28/2022
06/29/2022
06/30/2022
07/01/2022
Date
66.62(c)
66.44(c)
66.04(c)
66.68(c)
67.42(c)
Last
633 123
591 584
455 821
958 934
580 426
Volume
+0.73% -0.27% -0.60% +0.97% +1.11% Change
Estimated financial data (e) (USD)
Sales 2022
8 835 M - -
Net income 2022
571 M - -
Net Debt 2022
2 270 M - -
P/E ratio 2022
59,8x
Yield 2022
0,27%
Sales 2023
9 346 M - -
Net income 2023
797 M - -
Net Debt 2023
1 452 M - -
P/E ratio 2023
43,5x
Yield 2023
0,35%
Capitalization
34 407 M 34 407 M -
EV / Sales 2022
4,15x
EV / Sales 2023
3,84x
Nbr of Employees
24 000
Free-Float
98,0%
Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows:
- ophthalmic surgical products and equipment (54.9%): consumables (52.6% of net sales), implantable products (30.4%) and other products (17%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive...
All news about ALCON INC.
06/16 Argus Adjusts Alcon Price Target to $78 From $88, Maintains Buy Rating MT
06/06 Football Star Cooper Kupp Encourages Eye Allergy Sufferers to Find the Right Tool for t.. BU
05/25 GLOBAL MARKETS LIVE : Glencore, Starbucks, Apple, Lyft, Intuit...05/24 Swiss Eye Care Company Alcon Prices $536 Million Note Offering MT
05/24 Alcon Prices Public Offering of 500 Million Euros of Senior Notes MT
05/24 Alcon Prices EUR 500.0 Million Senior Notes Offering BU
05/24 Game Developer -BLADE RUNNER RPG on Kickstarter - Three Days Left AQ
05/23 GLOBAL MARKETS LIVE : Tesla, Kohl's, Apple, JPMorgan, Bank of America...05/23 Kala Announces Entry into Definitive Agreement to Sell EYSUVIS and INVELTYS to Alcon In.. AQ
05/23 Kala Pharmaceuticals to Sell EYSUVIS, INVELTYS to Alcon MT
05/23 Switzerland's Alcon To Purchase Eysuvis Eye Drops From Kala Pharmaceuticals For $60 Mil.. MT
05/23 Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio BU
05/20 Moody's Reiterates Alcon Ratings As Aging Population Drives Eye Care Demand MT
05/12 Alcon's Continued Recovery From COVID Drove Q1 Beat Despite 'Increased' Currency, Infla.. MT
05/12 Morgan Stanley Adjusts Price Target for Alcon to $83 From $92, Maintains Equalweight Ra.. MT
News in other languages on ALCON INC.
Analyst Recommendations on ALCON INC.
ALCON INC. - 03/02
The trend should regain control
BUY
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ALCON INC.
Short Term Mid-Term Long Term Trends Bearish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
70,03 $
Average target price
83,44 $
Spread / Average Target
19,1%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
